168 related articles for article (PubMed ID: 32866231)
1. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
Olsson H; Nordström T; Jäderling F; Egevad L; Vigneswaran HT; Annerstedt M; Grönberg H; Eklund M; Lantz A
J Natl Cancer Inst; 2021 May; 113(5):632-640. PubMed ID: 32866231
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
4. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
[TBL] [Abstract][Full Text] [Related]
5. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
6. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
7. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
8. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.
Dieffenbacher S; Nyarangi-Dix J; Giganti F; Bonekamp D; Kesch C; Müller-Wolf MB; Schütz V; Gasch C; Hatiboglu G; Hauffe M; Stenzinger A; Duensing S; Schlemmer HP; Moore CM; Hohenfellner M; Radtke JP
Eur Urol Focus; 2021 Jan; 7(1):102-110. PubMed ID: 30878348
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
[TBL] [Abstract][Full Text] [Related]
10. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
12. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
14. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
[TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
20. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
